Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research

2 abstracts

Abstract
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.
Org: Princess Margaret Cancer Centre, Wakayama Medical University, Wakayama, Japan, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Jilin Cancer Hospital, Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research,
Abstract
ABR-224050 A NOVEL DIHYDROOROTATE DEHYDROGENASE INHIBITOR SUPPRESSING DISEASE DEVELOPMENT IN COLLAGEN INDUCED ARTHRITIS IN DBA/1 MICE
Org: Research and Development Laboratories, Active Biotech Research AB, Lund, Sweden, Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Chelsea Therapeutics,